Generic Or Brand Name
You can call it with NVS Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines and Diagnostics division provides preventive vaccines and diagnostic tools. This division sells influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. Its Sandoz division provides prescription medicines, as well as pharmaceutical and biotechnological active substances. This division offers active ingredients and finished dosage forms of medicines; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; and cytotoxic products, as well as provides biotech manufacturing services to other companies. The company's Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC unit offers readily available consumer medicines. Animal Health unit provides veterinary products for farm and companion animals. CIBA Vision unit manufactures contact lenses and lens care products. It has strategic partnership with Lonza, a Swiss pharmaceuticals manufacturing company; and a research collaboration agreement with BioVista LLC. The company was founded in 1895 and is headquartered in Basel, Switzerland.
This one might have it all. If you are looking for a core pharmaceutical, this could be your play. Your time line should be 6-24 months. We had a position on NVO (not to be confused with this stock NVS) back in April and stopped out with a 7.8% loss. We have been on the look out for another pharm. We are liking what we are seeing.
First off we like the yield at close to 4%. Dividend hounds check this one out. It is a sustainable yield with a payout ratio of less than 50%. Its price to book is a reasonable 2.1. Its P/E is 14 and change and the forward looking multiple is under 11. Nearly every key stat is leading the industry.
Its fair value is in the range of 70 and 71 and is currently selling for 61 and change. That creates a decent 15% margin of safety. In taking a broader look, as we have said many times in the blog we have done well in the pharm sector. The last time was during the SARs and Swine Flu epidemic. It may have been ambulance chasing, but we did well.
The sector had been tired and beat up with the advent of proprietary drugs drying up, tougher and more convoluted FDA requirements, and government health care initiative being blurry at best. Yet we keep looking because we believe in the underlying demand as we live in a world made better by chemistry.
We think we might have a core investment opportunity with NVS. Novartis is more than just a pharm, they do consumer products, diagnostics as well as brand and generic drugs and vaccines. Acquisitions over the last several years (Sandoz, Chiron, and Alcon) have really widened the competitive more for this Swiss enterprise.
This would be a good stock to ease into and start collecting those dividends. We would suggest a long position bought in over a period of 3-5 weeks chipping away 20% sections of you desired position. We would say try and accumulate under 63 so buy on the dips. Put a stop in at 57.00 just to watch your downside and hang onto it until we see it break out of the 60-64 range it has been channeling in for the last several months.

It could be just what the doctor ordered.
Salve Lucrum